4//SEC Filing
Horizon Pharma plc 4
Accession 0001209191-14-059072
CIK 0001492426operating
Filed
Sep 21, 8:00 PM ET
Accepted
Sep 22, 7:09 PM ET
Size
26.9 KB
Accession
0001209191-14-059072
Insider Transaction Report
Form 4
DE VAERE ROBERT J
EVP and CFO
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2014-09-19−47,654→ 0 totalExercise: $5.20Exp: 2020-02-02→ Common Stock (47,654 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-09-19−51,000→ 0 totalExercise: $2.40Exp: 2023-01-01→ Common Stock (51,000 underlying) - Disposition to Issuer
Restricted Stock Units
2014-09-19−62,000→ 0 total→ Common Stock (62,000 underlying) - Disposition to Issuer
Common Stock
2014-09-19−94,290→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2014-09-19−42,295→ 0 totalExercise: $12.94Exp: 2020-06-05→ Common Stock (42,295 underlying) - Disposition to Issuer
Restricted Stock Units
2014-09-19−16,416→ 0 total→ Common Stock (16,416 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-09-19−70,000→ 0 totalExercise: $7.61Exp: 2024-01-01→ Common Stock (70,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-09-19−53,621→ 0 totalExercise: $4.96Exp: 2021-12-07→ Common Stock (53,621 underlying) - Disposition to Issuer
Restricted Stock Units
2014-09-19−33,750→ 0 total→ Common Stock (33,750 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-09-19−46,335→ 0 totalExercise: $10.43Exp: 2018-10-05→ Common Stock (46,335 underlying)
Footnotes (7)
- [F1]Disposition in connection with the merger (the "Merger") contemplated by the Transaction Agreement and Plan of Merger among Horizon Pharma, Inc. (the "Issuer"), Vidara Therapeutics Holdings LLC, Horizon Pharma plc (formerly known as Vidara Therapeutics International Ltd.), Hamilton Holdings (USA), Inc. and Hamilton Merger Sub, Inc. Pursuant to the Merger, the outstanding securities of the Issuer are being canceled and automatically converted into securities of Horizon Pharma plc. The Reporting Person's acquisition of securities of Horizon Pharma plc in the Merger will be reported on a separate Form 4.
- [F2]The stock option is fully vested and exercisable. 25% of the shares subject to the option vested on the first anniversary of the grant date, and the remaining shares vested in 36 equal monthly installments thereafter.
- [F3]In connection with the Merger, the stock option has been assumed and converted into options to purchase the same number of ordinary shares of Horizon Pharma plc at the same exercise price and on substantially the same terms.
- [F4]The stock option vests in 48 equal monthly installments following the grant date of 1/2/2013. The option will become fully vested and immediately exercisable on the Separation Date as defined in that certain Executive Employment and Transition Agreement dated June 17, 2014.
- [F5]Each restricted stock unit represented a contingent right to receive one share of Horizon Pharma, Inc. common stock. Each restricted stock unit has been converted into a contingent right to receive one ordinary share of Horizon Pharma plc.
- [F6]The restricted stock units vest in four equal annual installments. The units will become fully vested on the Separation Date as defined in that certain Executive Employment and Transition Agreement dated June 17, 2014.
- [F7]The stock option vests in 48 equal monthly installments following the grant date of 1/2/2014. The option will become fully vested and immediately exercisable on the Separation Date as defined in that certain Executive Employment and Transition Agreement dated June 17, 2014.
Documents
Issuer
Horizon Pharma plc
CIK 0001492426
Entity typeoperating
IncorporatedIreland
Related Parties
1- filerCIK 0001492426
Filing Metadata
- Form type
- 4
- Filed
- Sep 21, 8:00 PM ET
- Accepted
- Sep 22, 7:09 PM ET
- Size
- 26.9 KB